Obesity drugs show early promise against the hormonal disorder PMOS, giving a suffering family hope

Key Points:

• Charlotte Touzalin and her mother Anne Schultz were diagnosed with polyendocrine metabolic ovarian syndrome (PMOS), a hormonal disorder affecting 1 in 8 women, after years of unexplained symptoms like weight gain, irregular periods, and facial hair growth.
• Touzalin participated in a study testing GLP-1 drugs, such as semaglutide, which showed promising results in reducing weight, lowering testosterone levels, improving insulin resistance, and normalizing menstrual cycles in women with PMOS.
• Early research from multiple studies indicates that GLP-1 medications can effectively target key metabolic issues in PMOS, though the drugs are not yet FDA-approved for this condition and insurance coverage remains a significant barrier.
• Doctors are increasingly prescribing GLP-1 drugs off-label for PMOS patients, but side effects and variable responses mean the treatment is not universally effective, and discontinuation often leads to weight regain.
• Touzalin’s experience highlights both the potential benefits of GLP-1 drugs for PMOS and the challenges patients face accessing these treatments, underscoring the need for broader approval and insurance support.